TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07018323: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease

Sponsor: Immunovant Sciences GmbH · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 210 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$398,400

Rescue Site Savings

+$265,600

Unlock Full NCT07018323 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07018323 Rescue Dossier →